CSPC PHARMACEUTGR Revenue vs. Cash And Equivalents
| CVGU Stock | EUR 2.26 0.04 1.74% |
For CSPC PHARMACEUTGR profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CSPC PHARMACEUTGR to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CSPC PHARMACEUTGR ADR4 utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CSPC PHARMACEUTGR's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CSPC PHARMACEUTGR ADR4 over time as well as its relative position and ranking within its peers.
CSPC |
CSPC PHARMACEUTGR ADR4 Cash And Equivalents vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining CSPC PHARMACEUTGR's current stock value. Our valuation model uses many indicators to compare CSPC PHARMACEUTGR value to that of its competitors to determine the firm's financial worth. CSPC PHARMACEUTGR ADR4 is the top company in revenue category among its peers. It also is number one stock in cash and equivalents category among its peers creating about 0.30 of Cash And Equivalents per Revenue. The ratio of Revenue to Cash And Equivalents for CSPC PHARMACEUTGR ADR4 is roughly 3.31 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CSPC PHARMACEUTGR's earnings, one of the primary drivers of an investment's value.CSPC Revenue vs. Competition
CSPC PHARMACEUTGR ADR4 is the top company in revenue category among its peers. Market size based on revenue of Drug Manufacturers—General industry is currently estimated at about 173.19 Billion. CSPC PHARMACEUTGR retains roughly 30.72 Billion in revenue claiming about 18% of equities under Drug Manufacturers—General industry.
CSPC Cash And Equivalents vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
CSPC PHARMACEUTGR |
| = | 30.72 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
CSPC PHARMACEUTGR |
| = | 9.28 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CSPC Cash And Equivalents Comparison
CSPC PHARMACEUTGR is currently under evaluation in cash and equivalents category among its peers.
CSPC PHARMACEUTGR Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in CSPC PHARMACEUTGR, profitability is also one of the essential criteria for including it into their portfolios because, without profit, CSPC PHARMACEUTGR will eventually generate negative long term returns. The profitability progress is the general direction of CSPC PHARMACEUTGR's change in net profit over the period of time. It can combine multiple indicators of CSPC PHARMACEUTGR, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the Peoples Republic of China, other Asian regions, the Americas, Europe, and internationally. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the Peoples Republic of China. CSPC PHARMACEUT operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 21527 people.
CSPC Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on CSPC PHARMACEUTGR. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of CSPC PHARMACEUTGR position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the CSPC PHARMACEUTGR's important profitability drivers and their relationship over time.
Use CSPC PHARMACEUTGR in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CSPC PHARMACEUTGR position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CSPC PHARMACEUTGR will appreciate offsetting losses from the drop in the long position's value.CSPC PHARMACEUTGR Pair Trading
CSPC PHARMACEUTGR ADR4 Pair Trading Analysis
The ability to find closely correlated positions to CSPC PHARMACEUTGR could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CSPC PHARMACEUTGR when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CSPC PHARMACEUTGR - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CSPC PHARMACEUTGR ADR4 to buy it.
The correlation of CSPC PHARMACEUTGR is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CSPC PHARMACEUTGR moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CSPC PHARMACEUTGR ADR4 moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CSPC PHARMACEUTGR can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your CSPC PHARMACEUTGR position
In addition to having CSPC PHARMACEUTGR in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Macroaxis Picks Thematic Idea Now
Macroaxis Picks
Daily selected watch list of stocks of large companies handpicked by Macroaxis Team based on their diversification potential. The Macroaxis Picks theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Picks Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in CSPC Stock
To fully project CSPC PHARMACEUTGR's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of CSPC PHARMACEUTGR ADR4 at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include CSPC PHARMACEUTGR's income statement, its balance sheet, and the statement of cash flows.